fig2
![[<sup>18</sup>F]FDG PET imaging evaluation on non-alcoholic fatty liver disease and hepatocellular carcinoma model treated with sorafenib](https://image.oaes.cc/c6dd0c1d-2cff-4b96-b6b0-ba59a9eb9a19/2679.fig.2.png)
Figure 2. Illustrative images of the CT, PET with [18F]FDG, and fusion PET/CT. Note that the sorafenib group shows 3 high uptake lesions in the liver, while the control group shows 5 high uptake lesions in the liver and 1 lesion in the right lung (indicated by white arrows in the fusion image)
